In recent years, the adipose tissue has emerged as an important endocrine organ. It is now recognized that besides storing energy the adipocytes also secrete several bioactive peptides, collectively called adipocytokines. Among these adipocytokines, leptin, the product of the ob gene, has been extensively investigated over the last decade. Skeletal muscle and adipose tissue, two major tissues involved in the regulation of glucose and fatty acids metabolism, have been consistently demonstrated to be directly affected by leptin. By binding to its receptors located in skeletal muscle and fat cells, leptin promotes energy dissipation and prevents fatty acid accumulation and 'lipotoxicity' in these tissues. On the other hand, under conditions of peripheral leptin resistance, such as observed in obese humans, the activation of pathways involved in fatty acid oxidation may be impaired. This leads to intracellular accumulation of lipid intermediates and causes insulin resistance. This review examines the metabolic pathways that are directly activated by leptin and how it regulates glucose and fatty acids metabolism in skeletal muscle and fat tissue. Furthermore, the impact of peripheral leptin resistance in these tissues leading to dysfunctional metabolic adaptations is also discussed.
Leptin arises predominantly (495%) from adipose tissue (especially subcutaneous depots) and its secretion is proportional to the size of whole-body adipose tissue mass and nutritional status. 1, 2 In humans, leptin is encoded by a gene located in chromosome 7q31.3, and is similar to that in rodents. 3 Leptin is translated as a 167 amino-acid protein with an amino-terminal secretory signal sequence of 21 amino acids. The signal sequence is functional and results in the translocation of leptin into microsomes with subsequent cleavage of the signal peptide. Therefore, leptin circulates in the blood as a 16 kDa protein with 146 amino acids. 4 It has been postulated that leptin serves as a regulator of energy balance. In fact, treatment of rodents with leptin injections significantly reduced food intake and fat mass and increased energy expenditure. [5] [6] [7] Additionally, exogenous administration of recombinant leptin reversed the typical diabetic phenotype of ob/ob mice and improved the metabolic defects inherent of these animals. [5] [6] [7] Interestingly, the normalization of glycemia and insulinemia in ob/ob mice was observed even before any alteration in body weight took place, indicating that leptin plays an important role in the regulation of glucose homeostasis independently of its weight reducing effects. [5] [6] [7] [8] Leptin exerts its effects by binding to its receptors located in several tissues throughout the body. The receptor for leptin (Ob-R) was first cloned from a mouse choroid plexus cDNA expression library 9 following identification of [ 125 I] leptin binding sites in this tissue. The receptor presents high homology with the gp130 subunit of the IL-6 receptor and is a member of the extended class I cytokine-receptor family 9 including interleukin-6 (IL-6), the granulocyte-colony stimulating factor (G-CSF) and the leukemia-inhibitory factor (LIF). 9, 10 However, the leptin receptor oligomerizes with itself but not with its closely related cytokine signal transducer gp130.
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At the cellular level, Ob-R is known to signal through cytoplasmic tyrosine kinases of the Janus kinase family (JAKs) and signal transducers and activators of transcription (STAT) pathway. [9] [10] [11] [12] Leptin binds to its receptor and initiates a phosphoryation cascade via the Jak/STAT pathway and increases phosphorylation of signal transducers and activators of transcription (STAT3). [9] [10] [11] [12] STAT3 dimerizes, translocates to the nucleus and regulates transcriptional activity of its target genes ( Figure 1 ). The human and murine leptin receptors are highly similar in amino-acid sequences for both the extracellular (78% identity) and intracellular domains (71% identity). 10 There are at least six isoforms of the Ob-R(a-f), which are products of a single lepr gene and result from alternative mRNA splicing and/or proteolytic processing. 10, [12] [13] [14] Ob-Rs can be classified as secreted (Ob-Re), short (Ob-Ra, c, d, and f), and long (Ob-Rb) forms ( Figure 2 ). All murine Ob-R isoforms share identical extracellular, ligand binding domain of 816 amino acids, while the intracellular domain of the Cterminus is different 9,15 ( Figure 2 ). Ob-Rb (also referred to as Ob-RL; L ¼ long) has a long cytoplasmic domain of approximately 320 amino acids containing the motifs (Box 1, Box 2, and three tyrosine residues to positions Y985, Y1077, and Y1138) required for full activation of the JAK/STAT intracellular signaling pathway. [10] [11] [12] [13] [14] [15] [16] Owing to the truncation of the intracellular domain, all short isoforms of Ob-R are considered not capable of intracellular signaling; however, it has been demonstrated that Ob-Ra elicits signal transduction (expression of immediate early genes, c-fos, c-jun, and jun-B) in CHO cells added with leptin. 17 Ob-Re is truncated before the membrane-spanning domain and is likely to be a secreted isoform of the receptor, which is believed to be involved in modulating the activity of circulating leptin 18 ( Figure 2 ). Most tissues, including the adipose tissue, skeletal muscle, pancreas, and liver express short and long forms of Ob-R. [19] [20] [21] Peripheral tissues in general express 10 times more mRNA encoding the short forms than the long form of Ob-R. 20, 21 In normal mouse tissues, the relative abundance of the long form expressed as a percentage of total Ob-R mRNA is: stomach (11%), small intestine (7%), pancreas (11%), skeletal muscle (8%), fat tissue (6%), liver (5%), heart (10%), and hypothalamus (36%). 20, 21 The presence of the long and short forms of the Ob-R in peripheral tissues gives support to the observations that leptin exerts direct physiological effects, independently of signaling to the central nervous system (CNS).
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Direct effects of leptin on glucose and lipid metabolism in skeletal muscle
Skeletal muscle is quantitatively the most important site for insulin-stimulated glucose disposal and for fatty acid oxidation. 25, 26 Also, it represents approximately 40% of total body mass in nonobese subjects, and can account for up to 30% of resting metabolic rate. 27 A direct effect of leptin in skeletal muscle may play a major role in the development of insulin resistance and obesity. Indeed, it has been demonstrated that leptin per se acutely raised basal glucose uptake in isolated soleus muscles from rats 28 and mice, 29 and in C 2 C 12 30 and L6 skeletal muscle cells. 31 Furthermore, leptin increased basal and insulin-stimulated glucose oxidation in rat muscles. dimer activates the JAk2 tyrosine kinase, which associates membrane-proximally with the receptor. Activated Jak2 phosphorylates itself and a number of substrates including Y985 and Y1138 of Ob-Rb, and also insulin receptor substrates (IRSs). IRS1 and 2 interact and activate PI3-k and engage downstream pathways involved in glucose uptake and metabolism. After phosphorylation of membrane-distal Y1138 of Ob-Rb by Jak2, STAT3 is recruited via its SH2 (Src homology) domain and becomes itself a substrate for Jak2. Subsequently, phosphorylated STAT3 dimerizes, translocates to the nucleus, and induces the expression of several genes, including those involved in fatty acid oxidation (CPT1, PGC1, ACO, etc), and also the suppressor of cytokine signaling (SOCS3). SOCS3 takes part in a feedback loop inhibiting leptin signaling by binding to Y985 and Y1077; however, binding affinity for Y1007 is much weaker (dashed line). PTP-1B is localized on the surface of the endoplasmic reticulum (ER), and is also involved in negative regulation of leptin signaling by dephosphorylation of Jak2 apparently after internalization of the leptinOb-Rb complex. Leptin signaling also increases intracellular AMP content, which may be responsible for directly activating AMPK. This, in turn, phosphorylates and inactivates ACC leading to reduction of malonyl-CoA formation and deinhibition of CPT1 activity, a rate limiting step for long-chain fatty acids transport into the mitochondria and for fatty acid oxidation. PM ¼ plasma membrane.
Regulation of glucose and fatty acids metabolism by leptin RB Ceddia In fact, it has been demonstrated that leptin directly increases oxygen consumption in soleus muscles isolated from lean mice but not in db/db mice, which have a dysfunctional long form of the leptin receptor. 33 Besides glucose metabolism, evidence has also been provided that leptin directly increases the production of 14 [34] [35] [36] humans, 37 and rats. 38 A similar response has also been reported in C 2 C 12 myotubes. 39 In intact soleus and EDL muscles, leptin and insulin had opposite effects on lipid metabolism, with leptin favoring lipid oxidation and insulin favoring lipid storage in TG. Hormone-induced alterations in muscle lipid metabolism were more pronounced in soleus than in EDL. The differences in response of soleus compared with that of EDL were probably due to differences in fiber type composition and metabolic characteristics. 35 Compared with EDL, soleus is highly oxidative and has higher activities of oxidative enzymes, more mitochondria, and a greater capacity to store and use lipid fuels. 40 The mechanism by which leptin directly affects glucose and fatty acid metabolism in skeletal muscle still remains to be fully determined. However, there seems to be a crosstalk between the leptin and the insulin signaling pathways at the levels of the insulin receptor substrate (IRS) and phosphatidylinositol-3 kinase (PI3-kinase) 19 ,41 ( Figure 1 ). According to data obtained from C 2 C 12 myotubes leptin activates JAK-2, which induces tyrosine phosphorylation of IRS-2 leading to activation of PI3-kinase and this is accompanied by an increase in glucose uptake. 30, 41 Also, a direct thermogenic effect of leptin on soleus muscle, which could influence glucose and fatty acid metabolism, has been demonstrated to be mediated by PI3-kinase signaling. 33 More recently, it was reported that leptin directly activates 5 0 -AMP-activated protein kinase (AMPK) in skeletal muscle. 36, 42 AMPK is a heterotrimeric enzyme that functions as a regulator of cellular metabolism in response to changes in the energy status of the cells. 43 When activated, AMPK shuts down anabolic pathways and promotes catabolism in response to a fall in the ATP/AMP ratio by phosphorylating key enzymes of intermediary metabolism. 43 AMPK also plays an important role in the contraction-and hypoxia-induced glucose uptake in muscle. 43, 44 Therefore, the observations that leptin increases in vitro 28, 29, 30, 31 and in vivo 28,45 glucose uptake and metabolism can be at least partially explained by the direct activation of AMPK in skeletal muscle by this hormone. AMPK activation also leads to an increase in fatty acid oxidation preventing it from accumulating in the muscle cell as TG or in other lipid fractions [46] [47] [48] (Figure 3 ). Importantly, Figure 2 Leptin receptor isoforms. There are at least six different isoforms of the leptin receptor Ob-R(a-f) in mouse. All share identical extracellular ligand-bind domains but they differ at the C-terminus. Five of the six have transmembrane domains but only Ob-Rb encodes all protein motifs capable of activating the Jak-Stat signal transduction pathway. JAKs associate constitutively with a conserved box 1 motif (intracellular amino acids 6-17), which is critical for JAK2 activation. A putative Box 2 motif (intracellular amino acids 49-60), apparently required for maximal activation of JAK2, has also been identified. Additionally, Ob-Rb has three conserved tyrosines in its cytoplasmic domain, corresponding to positions Y985, Y1077, and Y1138. The latter functions as a docking site for STAT3. Ob-Re is truncated before the membrane-spanning domain and is secreted. Ig ¼ immunoglobulin domain; CRD ¼ cytokine receptor domain; Fn3 ¼ fibronectin III domain.
Regulation of glucose and fatty acids metabolism by leptin RB Ceddia when the intracellular TG pool exceeds a certain amount, it becomes toxic ('lipotoxicity') 47, 49 and alters function within muscle cells leading to insulin resistance in animals and humans. 47, [49] [50] [51] Interestingly, hyperleptinemic rats, induced by adenovirus gene transfer, presented a profound reduction in muscle TG content. 52 The TG content of skeletal muscle extracted from hyperleptinemic rats was 8% of the free feeding control rats and 25% of pair fed controls. 52 When tissue TG content is severely depleted by hyperleptinemia in normal rats, there is a dramatic increase in insulin sensitivity. [52] [53] [54] Whether this is a direct effect of leptin or mediated by the CNS still remains to be determined. However, treatment of high-fat-fed rats (60% fat for 8 days) with adenovirus coding for leptin raises plasma leptin levels up to 60 ng/ml without changing cocaine-and amphetamineregulated transcript (CART) mRNA or food intake, indicating that leptin action on the hypothalamus had not been increased. Nevertheless, their body fat declined 36%, suggesting that an extra-hypothalamic mechanism was responsible for this effect of leptin. 55 Support for a direct 'antilipotoxic' effect of leptin on skeletal muscle also comes from the observations that activation of AMPK by 5 0 aminoimidazole-4-carboxamide-1-b-D-ribonucleoside (AICAR) ameliorated fatty acid inducedinduced insulin resistance in isolated rat extensor digitorum longus muscle and this effect was abolished by an AMPKspecific inhibitor. 56 Also, blocking AMPK activation, by using a dominant negative strategy, 35 Figure 3 Schematic model of the direct effects of leptin on glucose and fatty acids metabolism in skeletal muscle. When leptin binds to its receptor (Ob-Rb), AMPK is phosphorylated and activated (1), which in turn phosphorylates and inactivates ACC (2) . This leads to a reduction in malonyl-CoA formation (3), deinhibition of carnitine palmitoyltransferase (CPT1) (4), and increase in fatty acid oxidation (5) . The increase in fatty acid oxidation reduces the formation of a diacylglycerol (DAG) pool from long-chain fatty acyl-CoA (FA-CoA) (6) and prevents the toxic effects of lipid intermediates. In the absence of leptin or under conditions of leptin resistance, nonesterified fatty acids (NEFA) accumulate in the cell, DAG is formed (6) and the insulin signaling cascade follows an abnormal pathway (dashed lines). DAG serves to activate a serine kinase, possibly protein kinase C (PKC)-y (7). PKCy phosphorylates the insulin receptor substrate (IRS)-1 on a serine residue (8) and interferes with the ability of insulin (through its receptor, IR) to phosphorylate IRS-1 on a tyrosine residue (9) and recruit and activate phosphatidylinositol 3-kinase (PI3-K) (10) . The net effect, therefore, is loss of the stimulus for GLUT4 translocation to the cell surface promoted by PI3-K (11) and impairment of insulin-stimulated glucose uptake (12) and metabolism. PM ¼ plasma membrane.
Regulation of glucose and fatty acids metabolism by leptin RB Ceddia (PKCy), 58 a known serine kinase that has been shown to be activated by diacylglycerol. Based on this information, a new mechanism has been proposed: increasing intracellular fatty acid metabolites, such as diaylglycerol or fatty acyl CoAs, activates a serine/threonine kinase cascade or protein kinase C, leading to phosphorylation of serine/threonine sites on insulin receptor substrates. 58, 59 Serine-phosphorylated forms of these proteins fail to associate with an active PI3-kinase resulting in decreased activation of glucose transport and other associated downstream events 25, 51 leading to insulin resistance ( Figure 3) . Either from the glucose-fatty acid cycle 57 or from the PKC activation perspectives, 58, 59 prevention of intramyocellular lipid accumulation seems to be an important mechanism by which leptin may protect from the development of NEFAinduced insulin resistance in skeletal muscle. Through its intracellular signaling pathways, leptin directly phosphorylates and activates AMPK, which in turn phosphorylates and inactivates ACC and releases the inhibition on carnitine palmitoyltransferase-1 (CPT1) 60, 61 by reducing intracellular malonyl-CoA levels. This results in upregulation of fatty acids oxidation and downregulation of lipid synthesis. 43, 44, [46] [47] [48] The direct activation of AMPK in skeletal muscle by leptin 36 may represent an important pathway that prevents lipotoxicity in this tissue ( Figure 3 ).
Direct effects of leptin on glucose and lipid metabolism in adipose tissue
The administration of leptin in vivo causes dramatic reduction of fat depots in rodents. [5] [6] [7] [8] For instance, epididymal white adipose tissue practically disappeared in lean C57BL/6 mice treated with human recombinant leptin. 62 Molecular analysis of adipose tissue revealed a rapid, selective increase in the mRNA expression of thermogenic proteins and lipolytic enzymes, including uncoupling proteins 1 and 2, lipoprotein lipase, and hormone-sensitive lipase, with decreases in the lipogenic enzyme fatty acid synthase, endogenous leptin, and cytochrome c oxidase. 62 These peripheral effects of leptin were followed by increased thermogenesis and lipid oxidation in brown fat coupled with increased lipolysis and decreased fat synthesis in white and brown fat, which led to a rapid reduction in the body weight and adiposity of lean C57BL/6 mice. 62 Also TG stores were strongly depleted in normal Wistar and lean wild-type diabetic fatty (ZDF) rats in which hyperleptinemia was induced by the injection of recombinant adenovirus containing the rat leptin cDNA. 53, 63 These in vivo effects could be explained by leptin acting via the hypothalamus but they do not rule out concomitant autocrine/paracrine effect of this hormone that could be mediated by the long form of the leptin receptor which is present in adipocytes. 20, 21 In fact, it has been demonstrated in isolated adipocytes that leptin reduces the binding of insulin to its receptor, 64 impairs insulin signaling, 65 reduces the metabolic actions of insulin on glucose uptake, glycogen synthesis, lipogenesis, 66, 67 and the incorporation of glucose 68 and acetate into lipids. 68, 69 Additionally, the expression of fatty acid synthase (FAS) and ACC, 63, 67, 70 and the maximal activity of malic enzyme, 68 which are involved in the fatty acids synthesis pathway, have also been shown to be reduced by leptin. On the other hand, in the same cell system, leptin has been reported to increase the expression of acyl-CoA oxidase (ACO), CPT1, peroxisome proliferator-activated receptor-a (PPAR-a), 70 and uncoupling protein-2 (UCP2), 69 and to promote glucose 68 and fatty acids oxidation, [66] [67] [68] [69] [70] [71] and lypolysis. 66, 70, 71 More recently, it was also demonstrated that hyperleptinemia increases the expression of PPAR gamma coactivator-1 (PGC-1, an upregulator of mitochondrial biogenesis), promotes the phosphorylation of AMPK and ACC and rapidly (up to 14 days) transforms the adipocytes into 'fat-oxidizing machines' in rats. 72 All these observations from in vivo and in vitro animal studies suggest that leptin should promote energy dissipation and limit lipid deposition in fat cells. Intriguingly, in human obesity and in some animal models of obesity the interstitial concentration of leptin surrounding adipocytes are extremely high 73 and yet excessive lipid storage in these cells is obviously not prevented. Apparently, there is a suppressive mechanism that impairs leptin action in fat tissue. This could be achieved by blocking signal transduction by the leptin receptor in adipocytes. In fact, it has been demonstrated that Socs-1 and 3 proteins are increased in adipocytes of diet-induced and ventromedial hypothalamus lesion (VMH) animal models of obesity. 73 As previously described, Socs proteins have been shown to block the action of leptin on STAT-3 phosphorylation, 74-77 a major pathway of intracellular leptin signal transduction, which is consistent with the generation of leptin resistance in fat cells and prevention of the autocrine and paracrine effects of this hormone. The importance of the direct effect of leptin on adipose tissue has been reinforced with the in vivo studies of adipocyte-selective reduction of the leptin receptors induced by antisense RNA. This study provides evidence that leptin resistance (not necessarily restricted to the level of the receptor) in adipocytes increases adiposity, dyslipidemia, and insulin resistance, 78 suggesting that this may be the molecular link between obesity and type 2 diabetes. Indeed, fat tissue represents a large proportion of body mass (15-20% and 20-30% for healthy men and women, respectively, and more than 40% in obese subjects). 79 Therefore, dysfunctional responses to leptin in this tissue may be of great impact to whole-body glucose and fatty acid homeostasis.
Physiological and molecular mechanisms of leptin resistance
Since administration of leptin decreased food intake and increased energy expenditure, resulting in loss of fat mass, and correction of the diabetic phenotype in ob/ob mice, [5] [6] [7] [8] [9] Regulation of glucose and fatty acids metabolism by leptin RB Ceddia leptin initially was hailed as a potential cure for human obesity. However, with the exception of rare human patients with genetic leptin deficiency, 80 circulating leptin levels correlate well with body mass index (BMI) and total body fat mass. [81] [82] [83] In fact, obese individuals have elevated circulating leptin, suggesting that they are resistant to the effects of leptin. Indeed, although therapy with exogenous leptin in humans caused weight loss, the effects were modest (À7.1 kg after 6 months of subcutaneous leptin injection compared to À1.3 kg for the placebo group) in obese subjects. 84 Nonetheless, it was reported that the dose of leptin necessary to elicit significant alterations in body weight was very high (0.30 mg/kg per day) and the patients reached serum leptin concentrations as high as 667.0 ng/ml, while in the 'placebo group' it remained around 25 ng/ml. 84 This reinforced the notion that 'leptin resistance' has to be overcome in order to improve responsiveness to this hormone in obese humans. Whether resistance to leptin resides mainly in the CNS (in those areas involved with the control food intake and energy homeostasis) or in peripheral tissues involved in energy storage (adipocytes) and dissipation (skeletal muscle), still remains under debate. A number of potential mechanisms have been postulated to underlie leptin resistance, including defects in leptin access into the brain, the presence of negative regulators of leptin signaling, or in pathways/neurons that mediate downstream leptin action. 85, 86 All these postulated mechanisms are related to the action of leptin in the CNS 87, 88 and very little has been published regarding leptin resistance in peripheral tissues. It has been demonstrated that the transport of leptin across the blood-brain barrier is saturated at plasma leptin levels between 4 and 15 ng/ml, nevertheless, exogenously elevated plasma leptin levels (above 15 ng/ml) elicit reduction in fat mass and improvements of glucose uptake and insulin sensitivity in rats, 55, 70 suggesting that direct peripheral effects of leptin may be responsible for these metabolic alterations caused by leptin treatment. It has been repeatedly demonstrated that leptin exerts its effects by also acting directly in peripheral tissues such as skeletal muscle, 28, 29, 33, 34, 37, 38 fat tissue, 66, 68, 70, 71 pancreas, [89] [90] [91] and liver, 92 which play important roles in the regulation of glucose and fatty acids metabolism and whole-body energy homeostasis in mammals. Additionally, it has been reported that isolated soleus muscles from highfat diet-induced obese (HFDIO) rats are not sensitive to the leptin-induced increase in fatty acid oxidation, 38 suggesting that the development of leptin resistance in skeletal muscle may contribute to the intramuscular accumulation of lipids. This is in line with the observations that in isolated soleus muscles from HFDIO mice, leptin failed to increase oxygen consumption when compared to muscles isolated from the lean mice. 33 Similar results have also been reported in isolated rectus abdominal muscles from humans, showing that leptin increased the partitioning of fatty acids towards oxidation in muscles from lean but not from obese subjects. 37 Potential mechanisms by which leptin resistance is induced in peripheral tissues involves the suppressors of cytokine signaling (Socs) family of molecules 19, 74 and protein tyrosine phosphatase-1 (PTP-1B). 19 Peripheral leptin administration to mice rapidly induces Socs3 mRNA expression in the brain. 75 Socs3 binds to the phosphorylated leptin receptor through its Src homology-2 (SH2) domain and inhibits Jak tyrosine kinase activity through its N-terminal kinase inhibitory region, which functions as a pseudosubstrate. [74] [75] [76] [77] Thus, Socs3 may be an important regulator of leptin signaling and seems to play a major role in the generation of peripheral leptin resistance. PTP-1B has also been involved in leptin sensitivity. Mice lacking PTP-1B are resistant to developing obesity, despite having low serum leptin levels, 93 indicating that this phosphatase might function as a negative regulator of leptin signaling. Further in vivo and in vitro experiments have confirmed that PTP-1B deficiency increases leptin sensitivity. 19 The mechanisms of this effect are not known. However, it has been demonstrated that PTP-1B recognizes a specific consensus substrate motif, (E/D)-pY-p-(R/K), which was identified in Jak2, 94, 95 and this is supposed to impair leptin-induced phosphorylation of Jak2. 12 How PTP-1B interacts with its substrates is not yet clear, although prior internalization of the receptor complex has been suggested, especially since PTP-1B is localized exclusively on the endoplasmic reticulum (ER) 96 and Jak2 has been detected at the ER. 97 
Conclusions and future directions
There is now compelling evidence that leptin is capable of directly regulating glucose and fatty acids metabolism in skeletal muscle and fat tissue. These tissues play important roles in whole-body glucose and lipid homeostasis, and are implicated in the development of obesity, insulin resistance, and type 2 diabetes. A number of molecular mechanisms and metabolic pathways whereby leptin exerts its direct peripheral effects have been identified. Several connections have been established between the leptin and intracellular signaling pathways in major insulin-sensitive tissues such as skeletal muscle and fat tissue. Also, the recent discovery that leptin directly activates AMPK revealed at least one mechanistic explanation for the antiobesity and antidiabetic roles that have been attributed to this hormone. Although great progress has been made in the last few years towards understanding the physiological roles of leptin, several fundamental questions still need to be answered in order to advance in the utilization of leptin or leptinomimetic drugs to treat human obesity. What causes leptin resistance and how can we prevent or reverse it? Are there specific dietary components that impair leptin signaling and induce resistance to this hormone in peripheral tissues? In rodents, long-term exposure to high-fat diet induces peripheral leptin resistance 73, 98 and this is also accompanied by high blood
Regulation of glucose and fatty acids metabolism by leptin RB Ceddia levels of NEFA and insulin resistance. 73, 98 NEFA also act as signals involved in the regulation of gene expression. Several genes are turned on by non-metabolized long-chain fatty acids in a physiologically relevant manner. 99, 100 Therefore, it can be hypothesized that chronically elevated fatty acids, as observed in obese subjects, 78, 101, 102 may induce the expression of genes involved in the generation of leptin resistance. To date, no studies have investigated whether chronic exposure of skeletal muscle to high levels of fatty acids may affect the direct action of leptin in this tissue. If fatty acids affect the expression and content of proteins such as Socs3 and PTP-1B, involved in the generation of leptin resistance, then this could impair the activation of the AMPK pathway by leptin and facilitate intramyocellular accumulation of fatty acids, leading to lipotoxicity and insulin resistance. Although no cause-effect relationship has been established between fatty acids and hyperleptinemia. Future experiments might help to clarify whether or not fatty acids can directly affect the molecular pathways involved in leptin signaling and the generation of leptin resistance in peripheral tissues. Answering these questions may lead to the discovery of drugs to treat obesity and its related metabolic disorders that are safer and more effective than the currently available.
